Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Wnt family member 9B (WNT9B)
- Target
- WNT9B
- Molecular classification
- Secreted signaling protein, Wnt family, Canonical Wnt pathway ligand, Regulatory ligand for frizzled receptors
01
Overview
Wnt family member 9B is a glycoprotein ligand of the frizzled receptor family, operating within the canonical Wnt/β-catenin signaling pathway. It is essential for embryonic development, particularly for the morphogenesis of the kidney and craniofacial structures. WNT9B transduces extracellular signals into intracellular responses, influencing gene transcription, cell proliferation, and differentiation. Dysregulation is linked to congenital malformations such as renal agenesis and cleft palate, and WNT9B has emerged as a potential biomarker for certain cancers, including breast cancer. Therapeutic targeting of WNT9B or its pathway requires caution due to widespread developmental roles and tumorigenic potential.
- Other names
- Protein Wnt-9bWNT9BWNT14BWNT15Protein Wnt-14bProtein Wnt-15wingless-type MMTV integration site family member 9Bwingless-type MMTV integration site family, member 15
02
Mechanism of action
Activation or inhibition of Wnt/β-catenin signaling via ligand-receptor interaction (usually with frizzled and LRP family receptors)
03
Biological functions
Signal transductionCell fate determinationRegulation of morphogenesisEmbryonic developmentRegulation of cell proliferation and differentiation
04
Disease associations
Developmental abnormalitiesCancerPituitary hormone deficiency
05
Safety considerations
Therapeutic modulation of Wnt signaling presents safety challenges due to its central role in development and cell proliferation; risks include unwarranted effects in differentiation, proliferation, oncogenesis, and disruption of normal embryogenesisPotential for off-target developmental toxicity and tumorigenesis
06
Interacting drugs
No clinically approved drugs are currently known to specifically target WNT9B. Wnt pathway modulators (investigational, pan-Wnt ligands, or frizzled antagonists) may indirectly affect WNT9B, but no direct drugs are listed in current databases or literature
07
Biomarkers
WNT9B expression is a sensitive and specific marker for breast cancerNo widely established companion diagnostics for WNT9B, but aberrant expression may predict developmental or oncogenic processes
Beyond the preview
Go deeper on Wnt family member 9B (WNT9B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wnt family member 9B (WNT9B).